Terms: = Kidney tumors AND GNAS, RP4-543J19_4, 2778, ENSG00000087460, NESP55, NESP, GSP, POH, GNASXL, GNAS1, C20orf45, dJ309F20_1_1, SCG6, GPSA, Gnas, dJ806M20_3_3, XL2, MGC33735, XL, PHP1A, GSA, AHO, XLalphas, PHP1B AND Treatment
8883 results:
1. Does depressurization of the portal vein before liver transplantation affect the recurrence of HCC? A nested case-control study.
Wei G; Zhao Y; Feng S; Yuan J; Xu G; Lv T; Yang J; Kong L; Yang J
BMC Cancer; 2024 May; 24(1):558. PubMed ID: 38702621
[TBL] [Abstract] [Full Text] [Related]
2. A retrospective clinical analysis of 11 cases of PEComa from different sites.
Yan J; Zhou D; Wang Y; Yang B; Wang Y; Zhang K; Zhang S; Zhang B; Meng Q; Lv Q
World J Surg Oncol; 2024 Apr; 22(1):116. PubMed ID: 38689335
[TBL] [Abstract] [Full Text] [Related]
3. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.
Rahman SN; Long JB; Westvold SJ; Leapman MS; Spees LP; Hurwitz ME; McManus HD; Gross CP; Wheeler SB; Dinan MA
JAMA Netw Open; 2024 Apr; 7(4):e248747. PubMed ID: 38687479
[TBL] [Abstract] [Full Text] [Related]
4. Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate.
Pitakkitnukun P; Pongpitakmetha T; Suttichet TB; Sukkummee W; Chariyavilaskul P; Polprasert C
Sci Rep; 2024 Apr; 14(1):9695. PubMed ID: 38678107
[TBL] [Abstract] [Full Text] [Related]
5. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract] [Full Text] [Related]
6. Squamous Cell Carcinoma Arising From Epidermal Cyst: A Case Series of 9 Patients With a Literature Review.
Kim JY; Min S; Park JK; Kim SW
Ann Plast Surg; 2024 May; 92(5):575-579. PubMed ID: 38669586
[TBL] [Abstract] [Full Text] [Related]
7. Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.
Pei F; Tao Z; Lu Q; Fang T; Peng S
World J Surg Oncol; 2024 Apr; 22(1):110. PubMed ID: 38664770
[TBL] [Abstract] [Full Text] [Related]
8. Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma.
Nakanishi S; Goya M; Suda T; Yonamine T; Sugawa A; Saito S
BMC Urol; 2024 Apr; 24(1):94. PubMed ID: 38658967
[TBL] [Abstract] [Full Text] [Related]
9. Comparison of skin cancer risk between renal transplant recipients and patients with glomerular diseases in rural Queensland.
Thet Z; Lam AK; Ng SK; Aung SY; Han T; Ranganathan D; Newsham S; Borg J; Pepito C; Khoo TK
Aust J Rural Health; 2024 Apr; 32(2):249-262. PubMed ID: 38646861
[TBL] [Abstract] [Full Text] [Related]
10. A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma.
Xu J; Zhang W; Tong J; Liu C; Zhang Q; Cao L; Yu J; Zhou A; Ma J
Cancer Immunol Immunother; 2024 Apr; 73(6):107. PubMed ID: 38642109
[TBL] [Abstract] [Full Text] [Related]
11. Ablation of kidney tumors in Patients with Substantial kidney Impairment: Current Status.
Iguchi T; Matsui Y; Tomita K; Uka M; Umakoshi N; Kawabata T; Gobara H; Araki M; Hiraki T
Curr Oncol Rep; 2024 May; 26(5):573-582. PubMed ID: 38625653
[TBL] [Abstract] [Full Text] [Related]
12. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2024 May; 203():107181. PubMed ID: 38614375
[TBL] [Abstract] [Full Text] [Related]
13. treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Atkins MB; Jegede OA; Haas NB; Mcdermott DF; Bilen MA; Stein M; Sosman J; Alter R; Plimack ER; Ornstein MC; Hurwitz M; Peace DJ; Einstein D; Catalano PJ; Hammers H; Regan MM
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604810
[TBL] [Abstract] [Full Text] [Related]
14. Clinical safety and efficacy of microwave ablation for small renal masses.
Foret A; Haaga CB; Jain S; Baumgartner CO; Escott M; Henderson BR; O'Brien ST; Delacroix SE; Gills JRR; Westerman ME
Int Braz J Urol; 2024; 50(3):277-286. PubMed ID: 38598830
[TBL] [Abstract] [Full Text] [Related]
15. Ablative Radioembolization (SIRT) of a Large Inoperable Renal Cell Carcinoma Invading the Liver That Resulted in Hematuria Control and Complete Necrosis by mRECIST Criteria.
Spyridonidis I; Dimopoulos P; Spyridonidis T; Christopoulou A; Katsanos K
Clin Nucl Med; 2024 Jun; 49(6):557-558. PubMed ID: 38598452
[TBL] [Abstract] [Full Text] [Related]
16. [Discussion on the surgical timing of rupture and hemorrhage of renal angiomyolipoma].
Chen K; Deng S; Liu Z; Zhang H; Ma L; Zhang S
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):326-331. PubMed ID: 38595253
[TBL] [Abstract] [Full Text] [Related]
17. Conversion to Radical Nephrectomy From Robotic Partial Nephrectomy Is Most Commonly Due to Anatomic and Oncologic Complexity.
Wang Y; Wilder S; Butaney M; Hijazi M; Gandham D; Van Til M; Goldman B; Qi J; Mirza M; Johnson A; Rudoff M; Wenzler D; Rogers CG; Lane BR
J Urol; 2024 May; 211(5):669-676. PubMed ID: 38591701
[TBL] [Abstract] [Full Text] [Related]
18. Challenges and technical aspects in the management of muscle invasive bladder cancer as retrograde radical cystectomy with ileal conduit.
Nusrat NB; Rehman AU; Zafar N; Muhammad S; Bajwa SI; Imtiaz S
J Pak Med Assoc; 2024 Mar; 74(3):513-518. PubMed ID: 38591289
[TBL] [Abstract] [Full Text] [Related]
19. Safety and efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma and impaired kidney function.
Sengul N; Gültürk I; Yilmaz M; Celik E; Paksoy N; Yekedüz E; Ürün Y; Basaran M; Özgüroğlu M
Actas Urol Esp (Engl Ed); 2024 May; 48(4):273-280. PubMed ID: 38570033
[TBL] [Abstract] [Full Text] [Related]
20. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP; Tao Y; Licitra L; Burtness B; Tahara M; Rischin D; Alves G; Lima IPF; Hughes BGM; Pointreau Y; Aksoy S; Laban S; Greil R; Burian M; Hetnał M; Delord JP; Mesía R; Taberna M; Waldron JN; Simon C; Grégoire V; Harrington KJ; Swaby RF; Zhang Y; Gumuscu B; Bidadi B; Siu LL;
Lancet Oncol; 2024 May; 25(5):572-587. PubMed ID: 38561010
[TBL] [Abstract] [Full Text] [Related]
[Next]
